Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis
Status:
Completed
Trial end date:
2020-11-12
Target enrollment:
Participant gender:
Summary
A Phase 2, multicenter, randomized, placebo-controlled, double-blind, parallel-group study
for subjects with moderate to severe AD whose disease cannot be adequately controlled with
topical medications or for whom topical treatment is medically inadvisable.
Phase:
Phase 2
Details
Lead Sponsor:
Kyowa Kirin Pharmaceutical Development, Inc. Kyowa Kirin, Inc.